SE466259B
(sv)
|
1990-05-31 |
1992-01-20 |
Arne Forsgren |
Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
|
SE9201331D0
(sv)
*
|
1992-04-28 |
1992-04-28 |
Hightech Receptor C O Active |
Protein l och hybridproteiner daerav
|
US6153406A
(en)
*
|
1993-07-23 |
2000-11-28 |
North American Vaccine, Inc. |
Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
|
US6001564A
(en)
*
|
1994-09-12 |
1999-12-14 |
Infectio Diagnostic, Inc. |
Species specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
|
US20020055101A1
(en)
|
1995-09-11 |
2002-05-09 |
Michel G. Bergeron |
Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
|
AU716806B2
(en)
*
|
1995-04-17 |
2000-03-09 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
|
US5994066A
(en)
*
|
1995-09-11 |
1999-11-30 |
Infectio Diagnostic, Inc. |
Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
|
US20030049636A1
(en)
|
1999-05-03 |
2003-03-13 |
Bergeron Michel G. |
Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories
|
US20100267012A1
(en)
|
1997-11-04 |
2010-10-21 |
Bergeron Michel G |
Highly conserved genes and their use to generate probes and primers for detection of microorganisms
|
US20050033022A1
(en)
*
|
1997-09-26 |
2005-02-10 |
Smithkline Beecham Biologicals Sa |
Fusion proteins comprising HIV-1 Tat and/or Nef proteins
|
GB9727262D0
(en)
*
|
1997-12-24 |
1998-02-25 |
Smithkline Beecham Biolog |
Vaccine
|
WO1999040188A2
(fr)
|
1998-02-05 |
1999-08-12 |
Smithkline Beecham Biologicals S.A. |
Derives antigenes associes aux tumeurs de la famille mage, et sequences d'acides nucleiques codant ces derives, utilises pour la preparaiton de proteines de fusion et de compositions destinees a la vaccination
|
US7579160B2
(en)
|
1998-03-18 |
2009-08-25 |
Corixa Corporation |
Methods for the detection of cervical cancer
|
US6706262B1
(en)
|
1998-03-18 |
2004-03-16 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US6518256B1
(en)
|
1998-03-18 |
2003-02-11 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US6482597B1
(en)
|
1999-12-17 |
2002-11-19 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US6696247B2
(en)
|
1998-03-18 |
2004-02-24 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US7049063B2
(en)
|
1998-03-18 |
2006-05-23 |
Corixa Corporation |
Methods for diagnosis of lung cancer
|
US6660838B1
(en)
|
1998-03-18 |
2003-12-09 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US6737514B1
(en)
|
1998-12-22 |
2004-05-18 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US7258860B2
(en)
|
1998-03-18 |
2007-08-21 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6312695B1
(en)
|
1998-03-18 |
2001-11-06 |
Corixa Corporation |
Compounds and methods for therapy of lung cancer
|
US6960570B2
(en)
|
1998-03-18 |
2005-11-01 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6426072B1
(en)
|
2000-08-02 |
2002-07-30 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6531315B1
(en)
|
1998-03-18 |
2003-03-11 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6821518B1
(en)
|
1998-03-18 |
2004-11-23 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US6342231B1
(en)
|
1998-07-01 |
2002-01-29 |
Akzo Nobel N.V. |
Haemophilus parasuis vaccine and diagnostic
|
US6375952B1
(en)
|
1998-08-07 |
2002-04-23 |
University Of Washington |
Immunological herpes simplex virus antigens and methods for use thereof
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
JP2002531129A
(ja)
|
1998-12-08 |
2002-09-24 |
コリクサ コーポレイション |
クラミジア感染の処置および診断のための化合物および方法
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6579973B1
(en)
|
1998-12-28 |
2003-06-17 |
Corixa Corporation |
Compositions for the treatment and diagnosis of breast cancer and methods for their use
|
US7198920B1
(en)
*
|
1999-01-29 |
2007-04-03 |
Corika Corporation |
HER-2/neu fusion proteins
|
CA2363118A1
(fr)
*
|
1999-02-25 |
2000-08-31 |
Smithkline Beecham Biologicals S.A. |
Immunogenes comprenant un peptide et support derive de haemophilius influenzae
|
GB9909077D0
(en)
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Biolog |
Novel compositions
|
EP1880735A3
(fr)
|
1999-03-19 |
2008-03-12 |
GlaxoSmithKline Biologicals S.A. |
Vaccin
|
CZ20013527A3
(cs)
*
|
1999-04-02 |
2002-10-16 |
Corixa Corporation |
Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
|
US20040040205A1
(en)
*
|
2002-04-25 |
2004-03-04 |
Weder Donald E. |
Wrapper with decorative extension and method
|
EP1246935B1
(fr)
|
1999-09-28 |
2013-08-14 |
Geneohm Sciences Canada Inc. |
Genes a fort pouvoir de conservation et leur utilisation pour produire des sondes d'acide nucleique specifiques a l'espece, specifiques au gene, specifiques a la famille, specifiques au groupe et universelles et des sondes d'amplification, en vue de detecter et d'identifier rapidement des micro-orga
|
DK1265915T3
(da)
|
2000-02-23 |
2011-02-14 |
Glaxosmithkline Biolog Sa |
Nye forbindelser
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
WO2001081379A2
(fr)
|
2000-04-21 |
2001-11-01 |
Corixa Corporation |
Composes et procedes pour le traitement et le diagnostic d'une infection a chlamydia
|
PT2133100E
(pt)
|
2000-06-20 |
2012-01-11 |
Corixa Corp |
Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
|
AU2001273149A1
(en)
|
2000-06-28 |
2002-01-08 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
GB0108364D0
(en)
|
2001-04-03 |
2001-05-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
CA2783274C
(fr)
|
2000-06-29 |
2018-08-07 |
Glaxosmithkline Biologicals S.A. |
Composition de vaccin multivalent a dose reduite d'haemophilus influenza de type b
|
US7713544B2
(en)
*
|
2000-07-28 |
2010-05-11 |
Emory University |
Biological component comprising artificial membrane
|
US7229623B1
(en)
|
2000-08-03 |
2007-06-12 |
Corixa Corporation |
Her-2/neu fusion proteins
|
GB0022742D0
(en)
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
GB0025171D0
(en)
*
|
2000-10-13 |
2000-11-29 |
Smithkline Beecham Biolog |
Novel compounds
|
PT2266603E
(pt)
|
2000-10-18 |
2012-11-02 |
Glaxosmithkline Biolog Sa |
Vacinas tumorais
|
GB0025998D0
(en)
*
|
2000-10-24 |
2000-12-13 |
Smithkline Beecham Biolog |
Novel compounds
|
US7082569B2
(en)
|
2001-01-17 |
2006-07-25 |
Outlooksoft Corporation |
Systems and methods providing dynamic spreadsheet functionality
|
EP1383896A2
(fr)
*
|
2001-04-30 |
2004-01-28 |
GlaxoSmithKline Biologicals S.A. |
Antigenes d'hemophilus influenzae
|
JP2005504513A
(ja)
|
2001-05-09 |
2005-02-17 |
コリクサ コーポレイション |
前立腺癌の治療及び診断のための組成物及び方法
|
JP2003047482A
(ja)
*
|
2001-05-22 |
2003-02-18 |
Pfizer Prod Inc |
非アナフィラキシー誘発性IgEワクチン
|
CN1313617C
(zh)
*
|
2001-11-07 |
2007-05-02 |
曼康公司 |
编码靶相关抗原表位的表达载体及其设计方法
|
CA2860702C
(fr)
|
2001-12-17 |
2019-02-26 |
Corixa Corporation |
Compositions et procedes applicables a la therapie et au diagnostic pour la maladie intestinale inflammatoire
|
ATE414176T1
(de)
|
2002-07-18 |
2008-11-15 |
Univ Washington |
Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene
|
AU2003274511B2
(en)
|
2002-10-11 |
2009-06-04 |
Glaxosmithkline Biologicals S.A. |
Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
RU2544850C2
(ru)
|
2003-01-06 |
2015-03-20 |
Корикса Корпорейшн |
Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
|
WO2004067030A2
(fr)
|
2003-01-30 |
2004-08-12 |
Chiron Srl |
Vaccins injectables contre les multiples serogroupes du meningocoque
|
GB0313916D0
(en)
|
2003-06-16 |
2003-07-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
GB0321615D0
(en)
|
2003-09-15 |
2003-10-15 |
Glaxo Group Ltd |
Improvements in vaccination
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
ES2397923T3
(es)
|
2003-10-02 |
2013-03-12 |
Novartis Ag |
Vacunas líquidas para múltiples serogrupos meningocócicos
|
JP2005112827A
(ja)
*
|
2003-10-10 |
2005-04-28 |
National Institute Of Advanced Industrial & Technology |
抗体アフィニティ担体
|
GB0406013D0
(en)
|
2004-03-17 |
2004-04-21 |
Chiron Srl |
Analysis of saccharide vaccines without interference
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0411387D0
(en)
|
2004-05-21 |
2004-06-23 |
Chiron Srl |
Analysis of saccharide length
|
GB0413868D0
(en)
|
2004-06-21 |
2004-07-21 |
Chiron Srl |
Dimensional anlaysis of saccharide conjugates
|
EP2199801B1
(fr)
|
2004-07-14 |
2013-05-29 |
The Regents of The University of California |
Biomarqueurs pour la détection précoce du cancer des ovaires
|
CN102657855B
(zh)
|
2004-09-22 |
2015-12-09 |
葛兰素史密丝克莱恩生物有限公司 |
用于进行抗葡萄球菌接种的免疫原性组合物
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
GB0502096D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Purification of streptococcal capsular polysaccharide
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
MX291624B
(es)
|
2005-02-18 |
2011-11-04 |
Novartis Vaccines & Diagnostic |
Inmunogenos de escherichia coli uropatogenica.
|
AU2006214064B2
(en)
|
2005-02-18 |
2012-04-26 |
J. Craig Venter Institute, Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
GB0505518D0
(en)
|
2005-03-17 |
2005-04-27 |
Chiron Srl |
Combination vaccines with whole cell pertussis antigen
|
JP2008534594A
(ja)
|
2005-03-31 |
2008-08-28 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
クラミジア感染に対するワクチン
|
ME01334B
(me)
|
2005-04-08 |
2013-12-20 |
Wyeth Llc |
Polivalentni pripravak konjugata pneumokoknog polisaharida s proteinom
|
EP1871411A4
(fr)
|
2005-04-18 |
2010-07-21 |
Novartis Vaccines & Diagnostic |
Procede pour exprimer un antigene de surface de virus de l'hepatite b afin de preparer un vaccin
|
CA2607715C
(fr)
|
2005-04-29 |
2015-11-24 |
Glaxosmithkline Biologicals S.A. |
Nouvelle methode de prevention ou de traitement d'une infection par m tuberculosis
|
MX2007016403A
(es)
|
2005-06-27 |
2008-03-07 |
Glaxosmithkline Biolog Sa |
Composicion inmunogenica.
|
JP5135220B2
(ja)
|
2005-09-01 |
2013-02-06 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー |
血清群c髄膜炎菌を含む複数ワクチン接種
|
GB0522765D0
(en)
|
2005-11-08 |
2005-12-14 |
Chiron Srl |
Combination vaccine manufacture
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
AR058592A1
(es)
|
2005-12-22 |
2008-02-13 |
Glaxosmithkline Biolog Sa |
Vacuna
|
EP1981905B1
(fr)
|
2006-01-16 |
2016-08-31 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Vaccin contre chlamydia
|
CA2636566C
(fr)
|
2006-01-17 |
2018-03-13 |
Arne Forsgren |
Nouvelle proteine de haemophilus influenzae a surface exposee (proteine; pe)
|
US7868139B2
(en)
|
2006-01-24 |
2011-01-11 |
Uab Research Foundation |
Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
|
NZ572054A
(en)
|
2006-03-22 |
2011-12-22 |
Novartis Ag |
Regimens for immunisation with meningococcal conjugates
|
GB0605757D0
(en)
|
2006-03-22 |
2006-05-03 |
Chiron Srl |
Separation of conjugated and unconjugated components
|
NZ570805A
(en)
|
2006-03-30 |
2011-10-28 |
Glaxosmithkline Biolog Sa |
Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
|
US20100021424A1
(en)
|
2006-06-02 |
2010-01-28 |
Vincent Brichard |
Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy
|
GB0612854D0
(en)
|
2006-06-28 |
2006-08-09 |
Novartis Ag |
Saccharide analysis
|
JP2010500399A
(ja)
|
2006-08-16 |
2010-01-07 |
ノバルティス アーゲー |
尿路病原性大腸菌由来の免疫原
|
PL2097102T3
(pl)
|
2006-09-07 |
2012-10-31 |
Glaxosmithkline Biologicals Sa |
Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
|
US8309096B2
(en)
|
2007-01-15 |
2012-11-13 |
Glaxosmithkline Biologicals S.A. |
Fusion protein
|
EP2114993B1
(fr)
*
|
2007-01-15 |
2012-08-29 |
GlaxoSmithKline Biologicals SA |
Vaccin
|
DK2136836T3
(en)
|
2007-04-04 |
2017-04-10 |
Infectious Disease Res Inst |
Immunogenic compositions with mycobacterium tuberculosis polypeptides and fusions thereof
|
TW200914042A
(en)
|
2007-05-02 |
2009-04-01 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US20090035360A1
(en)
|
2007-05-24 |
2009-02-05 |
Dominique Ingrid Lemoine |
Lyophilised antigen composition
|
CN101883583B
(zh)
|
2007-06-26 |
2017-05-17 |
葛兰素史密丝克莱恩生物有限公司 |
含有肺炎链球菌荚膜多糖缀合物的疫苗
|
EP3539567A1
(fr)
|
2007-07-02 |
2019-09-18 |
Etubics Corporation |
Procédés et compositions permettant de produire un vecteur d'adénovirus destiné à être utilisé avec des vaccinations multiples
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
EP2201131B8
(fr)
|
2007-09-17 |
2014-12-10 |
MDxHealth SA |
Détection de méthylation améliorée
|
PT2200642E
(pt)
|
2007-10-19 |
2012-05-30 |
Novartis Ag |
Formulações de vacinas meningocócicas
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
CA2716212A1
(fr)
|
2008-02-21 |
2009-08-27 |
Novartis Ag |
Polypeptides fhbp a meningocoques
|
JP2012502898A
(ja)
*
|
2008-09-17 |
2012-02-02 |
ハンター・イミュノロジー・リミテッド |
分類不能(non−typeable)インフルエンザ菌(Haemophilusinfluenzae)ワクチンおよびその使用
|
EP2326992B1
(fr)
*
|
2008-09-19 |
2015-04-22 |
Schoeller Technocell GmbH & Co. KG |
Matériau d'enregistrement pour un procédé d'impression laser
|
WO2010042481A1
(fr)
|
2008-10-06 |
2010-04-15 |
University Of Chicago |
Compositions et procédés associés aux protéines bactériennes eap, emp, et/ou adsa
|
CA2777837C
(fr)
|
2008-10-27 |
2017-07-11 |
Novartis Ag |
Procede de purification
|
KR101644221B1
(ko)
|
2008-12-09 |
2016-07-29 |
화이자 백신스 엘엘씨 |
IgE CH3 펩티드 백신
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
GB0822633D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Formulation
|
US20100189737A1
(en)
|
2008-12-17 |
2010-07-29 |
Arico Beatrice |
Meningococcal vaccines including hemoglobin receptor
|
US7876118B2
(en)
|
2009-02-05 |
2011-01-25 |
Advantest Corporation |
Test equipment
|
EA021100B1
(ru)
|
2009-03-17 |
2015-04-30 |
МДхХЭЛС СА |
Усовершенствованное определение экспрессии генов
|
JP5668049B2
(ja)
|
2009-03-24 |
2015-02-12 |
ノバルティス アーゲー |
髄膜炎菌h因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
|
CA2756522C
(fr)
|
2009-03-24 |
2018-06-26 |
Novartis Ag |
Proteine de liaison du facteur h meningococcique utilisee comme adjuvant
|
PL2414387T3
(pl)
|
2009-04-03 |
2016-06-30 |
Univ Chicago |
Kompozycje i sposoby związane z wariantami białka A (SpA)
|
JP5830009B2
(ja)
|
2009-04-14 |
2015-12-09 |
ノバルティス アーゲー |
Staphylococcusaureusに対して免疫化するための組成物
|
RU2536248C2
(ru)
|
2009-04-30 |
2014-12-20 |
Коули Фармасьютикал Груп, Инк. |
Пневмококковая вакцина и ее применения
|
US8668911B2
(en)
|
2009-05-14 |
2014-03-11 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
NZ598356A
(en)
|
2009-07-30 |
2014-06-27 |
Pfizer Vaccines Llc |
Antigenic tau peptides and uses thereof
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
JP2013502918A
(ja)
|
2009-08-27 |
2013-01-31 |
ノバルティス アーゲー |
髄膜炎菌fHBP配列を含むハイブリッドポリペプチド
|
MX2012002639A
(es)
|
2009-09-03 |
2012-03-14 |
Pfizer Vaccines Llc |
Vacuna de pcsk9.
|
US20120237536A1
(en)
|
2009-09-10 |
2012-09-20 |
Novartis |
Combination vaccines against respiratory tract diseases
|
GB0917457D0
(en)
|
2009-10-06 |
2009-11-18 |
Glaxosmithkline Biolog Sa |
Method
|
US20130022639A1
(en)
|
2009-09-30 |
2013-01-24 |
Novartis Ag |
Expression of meningococcal fhbp polypeptides
|
US8974799B2
(en)
|
2009-09-30 |
2015-03-10 |
Novartis Ag |
Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
EP2493499A1
(fr)
|
2009-10-27 |
2012-09-05 |
Novartis AG |
Polypeptides fhbp méningococciques modifiés
|
DK2493498T3
(en)
|
2009-10-30 |
2017-05-08 |
Glaxosmithkline Biologicals Sa |
Purification of Staphylococcus aureus type 5 and type 8 capsule saccharides
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
KR20120129927A
(ko)
|
2010-01-27 |
2012-11-28 |
글락소 그룹 리미티드 |
변형된 투베르쿨로시스 항원
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
JP2013523818A
(ja)
|
2010-04-05 |
2013-06-17 |
ザ・ユニバーシティー・オブ・シカゴ |
免疫反応のエンハンサーとしてのプロテインA(SpA)抗体に関連する組成物および方法
|
EP2942061A3
(fr)
|
2010-06-07 |
2016-01-13 |
Pfizer Vaccines LLC |
Vaccin peptidique ige ch3
|
US10478483B2
(en)
|
2010-06-25 |
2019-11-19 |
Glaxosmithkline Biologicals Sa |
Combinations of meningococcal factor H binding proteins
|
KR20130093084A
(ko)
|
2010-07-02 |
2013-08-21 |
더 유니버시티 오브 시카고 |
단백질 A(SpA) 변이체와 관련된 조성물 및 방법
|
US9095540B2
(en)
|
2010-09-09 |
2015-08-04 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
US20130345079A1
(en)
|
2010-10-27 |
2013-12-26 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
ES2859673T3
(es)
|
2010-11-08 |
2021-10-04 |
Infectious Disease Res Inst |
Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis
|
WO2012072769A1
(fr)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Epitopes rrgb de pneumocoque et combinaisons de variantes
|
WO2012085668A2
(fr)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Composés
|
EP2668299B1
(fr)
*
|
2011-01-26 |
2018-03-07 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Détection sélective de haemophilus influenzae
|
EP2667852B1
(fr)
|
2011-01-27 |
2016-11-09 |
GlaxoSmithKline Biologicals SA |
Nanoémulsions d'adjuvant à inhibiteurs de cristallisation
|
BR112013022397A2
(pt)
|
2011-03-02 |
2017-09-26 |
Derek OHagan |
vacinas combinadas com doses menores de antígeno e/ou adjuvante
|
EP2680883B1
(fr)
|
2011-03-02 |
2018-09-05 |
Pfizer Inc |
Vaccin à base de pcsk9
|
GB201103836D0
(en)
|
2011-03-07 |
2011-04-20 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
ES2785108T3
(es)
|
2011-03-24 |
2020-10-05 |
Glaxosmithkline Biologicals Sa |
Nanoemulsiones adyuvantes con fosfolípidos
|
GB201105981D0
(en)
|
2011-04-08 |
2011-05-18 |
Glaxosmithkline Biolog Sa |
Novel process
|
TW201302779A
(zh)
|
2011-04-13 |
2013-01-16 |
Glaxosmithkline Biolog Sa |
融合蛋白質及組合疫苗
|
US20130156803A1
(en)
|
2011-06-04 |
2013-06-20 |
Rochester General Hospital Research Institute |
Compositions and methods related to p6
|
EP2729178A1
(fr)
|
2011-07-08 |
2014-05-14 |
Novartis AG |
Procédé de ligature de la tyrosine
|
MX2014000893A
(es)
|
2011-07-22 |
2014-05-30 |
Glaxosmithkline Biolog Sa |
Purificacion del antigeno expresado preferentemente en melanoma.
|
AU2012301955A1
(en)
|
2011-08-29 |
2014-03-06 |
The Regents Of The University Of California |
Use of HDL-related molecules to treat and prevent proinflammatory conditions
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201114919D0
(en)
|
2011-08-30 |
2011-10-12 |
Glaxosmithkline Biolog Sa |
Method
|
MX354924B
(es)
|
2011-11-07 |
2018-03-22 |
Novartis Ag |
Molecula portadora que comprende un antigeno spr0096 y un spr2021.
|
DE102011118371B4
(de)
|
2011-11-11 |
2014-02-13 |
Novartis Ag |
Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
|
GB2495341B
(en)
|
2011-11-11 |
2013-09-18 |
Novartis Ag |
Fermentation methods and their products
|
DE102011122891B4
(de)
|
2011-11-11 |
2014-12-24 |
Novartis Ag |
Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
|
EP2592137A1
(fr)
|
2011-11-11 |
2013-05-15 |
Novartis AG |
Support de fermentation sans composants dérivés d'animaux pour la production des toxoïdes diphtériques adaptées à l'utilisation du vaccin humain
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
WO2013098589A1
(fr)
|
2011-12-29 |
2013-07-04 |
Novartis Ag |
Combinaisons avec adjuvant de protéines méningococciques liant le facteur h
|
JP2015510872A
(ja)
|
2012-03-07 |
2015-04-13 |
ノバルティス アーゲー |
Streptococcuspneumoniae抗原の増強された製剤
|
CN104159603A
(zh)
|
2012-03-08 |
2014-11-19 |
诺华股份有限公司 |
带有tlr4激动剂的联合疫苗
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
BR112014026861A2
(pt)
|
2012-04-26 |
2018-05-15 |
Univ Chicago |
antígenos de estafilococos coagulase e métodos de seu uso
|
US10124051B2
(en)
|
2012-05-22 |
2018-11-13 |
Glaxosmithkline Biologicals Sa |
Meningococcus serogroup X conjugate
|
EP2666785A1
(fr)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Vaccins basés sur la protéine complément C5a
|
RU2659149C2
(ru)
|
2012-08-03 |
2018-06-28 |
Инфекшес Дизиз Рисерч Инститьют |
Композиции и способы для лечения активной инфекции mycobacterium tuberculosis
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
EP2703483A1
(fr)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
Vaccin à base de PCSK9
|
RU2015106930A
(ru)
|
2012-09-06 |
2016-10-20 |
Новартис Аг |
Комбинированные вакцины с менингококком серогруппы в и к/д/с
|
AR092897A1
(es)
|
2012-10-03 |
2015-05-06 |
Novartis Ag |
Composiciones inmunogenicas
|
KR20150065878A
(ko)
|
2012-10-12 |
2015-06-15 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
조합 백신에서 사용하기 위한 가교되지 않은 무세포 백일해 항원
|
SI2925355T1
(en)
|
2012-11-30 |
2018-04-30 |
Glaxosmithkline Biologicals S.A. |
Antigens and combinations of Pseudomonas antigens
|
US9827190B2
(en)
|
2013-02-01 |
2017-11-28 |
Glaxosmithkline Biologicals Sa |
Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
|
ES2728865T3
(es)
|
2013-03-28 |
2019-10-29 |
Infectious Disease Res Inst |
Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis
|
GB201310008D0
(en)
|
2013-06-05 |
2013-07-17 |
Glaxosmithkline Biolog Sa |
Immunogenic composition for use in therapy
|
MX369534B
(es)
|
2013-09-08 |
2019-11-11 |
Pfizer |
Composiciones de neisseria meningitidis y sus metodos.
|
WO2015095868A1
(fr)
|
2013-12-20 |
2015-06-25 |
Wake Forest University Health Sciences |
Méthodes et compositions permettant d'augmenter les taux d'anticorps protecteurs induits par des vaccins antipneumococciques polyosidiques
|
SI3583947T1
(sl)
|
2014-01-21 |
2024-01-31 |
Pfizer Inc. |
Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2015110940A2
(fr)
|
2014-01-21 |
2015-07-30 |
Pfizer Inc. |
Polysaccharides capsulaires de streptococcus pneumoniae et conjugués de ceux-ci
|
AU2015208821B2
(en)
|
2014-01-21 |
2017-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
ES2930318T3
(es)
|
2014-02-14 |
2022-12-09 |
Pfizer |
Conjugados glucoproteicos inmunogénicos
|
TW201620927A
(zh)
|
2014-02-24 |
2016-06-16 |
葛蘭素史密斯克藍生物品公司 |
Uspa2蛋白質構築體及其用途
|
SG11201606478YA
(en)
|
2014-02-28 |
2016-09-29 |
Glaxosmithkline Biolog Sa |
Modified meningococcal fhbp polypeptides
|
AU2015359503B2
(en)
|
2014-12-10 |
2019-05-09 |
Glaxosmithkline Biologicals Sa |
Method of treatment
|
EP3034516A1
(fr)
|
2014-12-19 |
2016-06-22 |
Novartis AG |
Purification de polysaccharides capsulaires de streptocoques
|
PL3244917T3
(pl)
|
2015-01-15 |
2023-07-17 |
Pfizer Inc. |
Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
|
US20180071380A1
(en)
|
2015-03-20 |
2018-03-15 |
The Regents Of The University Of Michigan |
Immunogenic compositions for use in vaccination against bordetella
|
KR102225282B1
(ko)
|
2015-07-21 |
2021-03-10 |
화이자 인코포레이티드 |
접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2017085586A1
(fr)
|
2015-11-20 |
2017-05-26 |
Pfizer Inc. |
Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
|
EA201891287A1
(ru)
|
2015-12-04 |
2018-11-30 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Вакцинация с использованием альфа 3-домена mica/b для лечения рака
|
BE1024634B1
(fr)
|
2016-04-05 |
2018-05-14 |
Gsk Vaccines S.R.L. |
Compositions immunogenes
|
WO2017205225A2
(fr)
|
2016-05-21 |
2017-11-30 |
Infectious Disease Research Institute |
Compositions et méthodes de traitement de la tuberculose secondaire et des infections à mycobacterium non tuberculeuses
|
EP3269385A1
(fr)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Composition de conjugués de polysaccharide-protéine pneumococcique
|
EP3474890A1
(fr)
|
2016-06-22 |
2019-05-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. |
Composition de conjugué polysaccharide pneumococcique-protéine
|
AU2017321039B2
(en)
|
2016-09-02 |
2021-03-18 |
Glaxosmithkline Biologicals Sa |
Vaccines for Neisseria gonorrhoeae
|
US20210108002A1
(en)
|
2016-12-06 |
2021-04-15 |
Glaxosmithkline Biologicals Sa |
Purification Process For Capsular Polysaccharide
|
GB201621686D0
(en)
|
2016-12-20 |
2017-02-01 |
Glaxosmithkline Biologicals Sa |
Novel methods for inducing an immune response
|
HRP20220573T1
(hr)
|
2017-01-20 |
2022-06-10 |
Pfizer Inc. |
Imunogeni pripravci, namijenjeni upotrebi u pneumokoknim cjepivima
|
SG11201906519RA
(en)
|
2017-01-31 |
2019-08-27 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
EP3576759A4
(fr)
|
2017-01-31 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Procédés de production de conjugués protéine-polysaccharide capsulaire à partir du sérotype 19f de streptococcus pneumoniae
|
WO2018178264A1
(fr)
|
2017-03-31 |
2018-10-04 |
Glaxosmithkline Intellectual Property Development Limited |
Composition immunogène, utilisation et méthode de traitement
|
WO2018178265A1
(fr)
|
2017-03-31 |
2018-10-04 |
Glaxosmithkline Intellectual Property Development Limited |
Composition immunogène, utilisation et procédé de traitement
|
IE87413B1
(en)
|
2017-05-30 |
2023-07-19 |
Glaxosmithkline Biologicals Sa |
Novel methods for manufacturing an adjuvant
|
BR112020001768A2
(pt)
*
|
2017-08-14 |
2020-09-29 |
Glaxosmithkline Biologicals S.A. |
método de reforçar uma resposta imune pré-existente contra haemophilus influenzae e moraxella catarrhalis não tipáveis em um indivíduo, e, protocolo de vacinação.
|
AU2018328037B2
(en)
|
2017-09-07 |
2024-03-07 |
Merck Sharp & Dohme Llc |
Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
|
MX2020005481A
(es)
|
2017-12-01 |
2020-12-07 |
Glaxosmithkline Biologicals Sa |
Purificacion de saponina.
|
SG11202005255PA
(en)
|
2017-12-06 |
2020-07-29 |
Merck Sharp & Dohme |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
WO2020016322A1
(fr)
|
2018-07-19 |
2020-01-23 |
Glaxosmithkline Biologicals Sa |
Procédés de préparation de polysaccharides séchés
|
MX2021001479A
(es)
|
2018-08-07 |
2021-04-28 |
Glaxosmithkline Biologicals Sa |
Novedosos procesos y vacunas.
|
EP3607967A1
(fr)
|
2018-08-09 |
2020-02-12 |
GlaxoSmithKline Biologicals S.A. |
Polypeptides modifiés du méningocoque fhbp
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
EP3886901A1
(fr)
|
2018-11-29 |
2021-10-06 |
GlaxoSmithKline Biologicals S.A. |
Procédés de fabrication d'un adjuvant
|
EP3894431A2
(fr)
|
2018-12-12 |
2021-10-20 |
GlaxoSmithKline Biologicals SA |
Protéines porteuses modifiées pour glycosylation à liaison o
|
EP3893926A1
(fr)
|
2018-12-12 |
2021-10-20 |
Pfizer Inc. |
Conjugués polysaccharide-protéine immunogènes à hétéroantigènes multiples et leurs utilisations
|
TWI788610B
(zh)
|
2018-12-19 |
2023-01-01 |
美商默沙東有限責任公司 |
包含肺炎鏈球菌多醣-蛋白質結合物之組合物及其使用方法
|
US20220118072A1
(en)
|
2019-02-11 |
2022-04-21 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
US20220184199A1
(en)
|
2019-04-10 |
2022-06-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
WO2020212461A1
(fr)
|
2019-04-18 |
2020-10-22 |
Glaxosmithkline Biologicals Sa |
Protéines de liaison à l'antigène et dosages
|
US20220211859A1
(en)
|
2019-05-10 |
2022-07-07 |
Glaxosmithkline Biologicals Sa |
Conjugate production
|
JP2022535091A
(ja)
|
2019-06-05 |
2022-08-04 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
サポニン精製
|
CA3148824A1
(fr)
|
2019-07-31 |
2021-02-04 |
Sanofi Pasteur Inc. |
Compositions de conjugues de polysaccharide-proteine pneumococcique multivalents leurs methodes d'utilisation
|
AU2020325645A1
(en)
|
2019-08-05 |
2022-02-17 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
WO2021023692A1
(fr)
|
2019-08-05 |
2021-02-11 |
Glaxosmithkline Biologicals Sa |
Procédé de préparation d'une composition comprenant un polypeptide de protéine d
|
CN115605222A
(zh)
|
2019-09-27 |
2023-01-13 |
辉瑞公司(Us) |
脑膜炎奈瑟氏菌组合物及其方法
|
MX2022005252A
(es)
|
2019-11-01 |
2022-06-08 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas.
|
MX2022006054A
(es)
|
2019-11-22 |
2022-06-24 |
Glaxosmithkline Biologicals Sa |
Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos.
|
CN115362177A
(zh)
|
2020-02-21 |
2022-11-18 |
辉瑞公司 |
糖类的纯化
|
MX2022010350A
(es)
|
2020-02-23 |
2022-09-19 |
Pfizer |
Composiciones de esquerichia coli y sus metodos.
|
EP4165064A2
(fr)
|
2020-06-12 |
2023-04-19 |
GlaxoSmithKline Biologicals S.A. |
Système d'étiquette-ancrage
|
GB202013262D0
(en)
|
2020-08-25 |
2020-10-07 |
Glaxosmithkline Biologicals Sa |
Vaccine Composition
|
EP4232593A1
(fr)
|
2020-10-22 |
2023-08-30 |
Pfizer Inc. |
Procédés de purification de polysaccharides bactériens
|
JP2023546615A
(ja)
|
2020-10-27 |
2023-11-06 |
ファイザー・インク |
大腸菌組成物およびその方法
|
AU2021373358A1
(en)
|
2020-11-04 |
2023-06-01 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
CA3200968A1
(fr)
|
2020-11-10 |
2022-05-19 |
Pfizer Inc. |
Compositions immunogenes comprenant des antigenes saccharidiques capsulaires conjugues et leurs utilisations
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
WO2022175423A1
(fr)
|
2021-02-22 |
2022-08-25 |
Glaxosmithkline Biologicals Sa |
Composition immunogène, utilisation et procédés
|
WO2022234416A1
(fr)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination contre des infections à pneumocoque et à covid-19
|
JP2024517780A
(ja)
|
2021-05-03 |
2024-04-23 |
ファイザー・インク |
細菌およびベータコロナウイルス感染症に対するワクチン接種
|
US20220387576A1
(en)
|
2021-05-28 |
2022-12-08 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2022249106A2
(fr)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
|
EP4398933A1
(fr)
|
2021-09-09 |
2024-07-17 |
Affinivax, Inc. |
Vaccins antipneumococciques multivalents
|
WO2023135515A1
(fr)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Compositions immunogènes à base d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
|
WO2023161817A1
(fr)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens
|
WO2023218322A1
(fr)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Procédé de production de formulations de vaccin avec des conservateurs
|
GB202208089D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
GB202208093D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
WO2024017827A1
(fr)
|
2022-07-19 |
2024-01-25 |
Glaxosmithkline Biologicals Sa |
Procédé continu de production de vaccin
|
WO2024084397A1
(fr)
|
2022-10-19 |
2024-04-25 |
Pfizer Inc. |
Vaccination contre infections à pneumocoques et à covid-19
|
WO2024110827A1
(fr)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Procédés de préparation d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
|
US20240181028A1
(en)
|
2022-11-22 |
2024-06-06 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(fr)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Formulations de vaccin pneumococcique conjugué
|